Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients

Table 5 Comparison of 20%-nonresponders vs. 20%-responders using the United Kingdom-derived equation

	20%-nonresponders^a	20%-responders^a	P-value
	Mean ± SE	Mean ± SE
Average of placebo run-in and randomization (Visits 0, 1, 2)	n = 212	n = 81
EQ-5D at baseline	0.570 ± 0.007	0.577 ± 0.009	NS
Week 2 (Visit 3)	n = 207	n = 79
Change from baseline, EQ-5D	0.004 ± 0.005	0.034 ± 0.007	0.001
Change from baseline, ES	0.067 ± 0.075	0.535 ± 0.115
Week 6 (Visit 4)	n = 206	n = 79
Change from baseline, EQ-5D	−0.004 ± 0.004	0.044 ± 0.009	<0.001
Change from baseline, ES	−0.055 ± 0.070	0.694 ± 0.144
Week 10 (Visit 5)	n = 202	n = 76
Change from baseline, EQ-5D	−0.012 ± 0.005	0.033 ± 0.009	<0.001
Change from baseline, ES	−0.195 ± 0.076	0.529 ± 0.144
Week 14 (Visit 6)	n = 201	n = 78
Change from baseline, EQ-5D	−0.024 ± 0.005	0.043 ± 0.011	<0.001
Change from baseline, ES	−0.376 ± 0.084	0.682 ± 0.173
Week 16 (Visit 7)	n = 207	n = 79
Change from baseline, EQ-5D	−0.037 ± 0.006	−0.015 ± 0.010	0.03
Change from baseline, ES	−0.590 ± 0.087	−0.232 ± 0.150
Week 18 (Visit 8)	n = 203	n = 79
Change from baseline, EQ-5D	−0.038 ± 0.005	−0.021 ± 0.010	NS
Change from baseline, ES	−0.596 ± 0.086	−0.331 ± 0.153

EQ-5D Euroqol 5-Dimension, ES effect size, NS not significant, SE standard error, T25FW Timed 25 Foot Walk.
See Figure 1D for graphical representation.
^a20%-nonresponder or 20%-responder status based on whether the mean of all T25FW scores during double-blind visits improved by 20% or more from the mean of the T25FW scores during pre-randomization visits.

ISSN: 1477-7525